The chaos Health and Human Services Secretary Robert Kennedy has injected into the U.S. vaccine market could have long-term consequences as vaccine makers reevaluate business decisions and pipelines. Read More
Amgen Inc. has swooped on two European cancer specialists, buying Dark Blue Therapeutics Ltd. for up to $840 million plus royalties, and sealing a $618 million license agreement with Disco Pharmaceuticals GmbH for rights to a novel cancer cell surface target. Read More
Monte Rosa Therapeutics Inc. followed up December’s positive prostate cancer data with strong interim findings from a phase I study with MRT-8102, a NEK7-directed molecular glue degrader in the works for inflammatory conditions driven by the NLRP3 inflammasome, IL-1, and IL-6. Read More
As widely expected, GSK plc and Ionis Pharmaceuticals Inc. reported positive findings from two pivotal trials testing bepirovirsen in chronic hepatitis B, showing the antisense oligonucleotide therapy achieved a statistically and clinically meaningful functional cure rate, indicating a potential transition in CHB treatment beyond the current viral suppression-focused standard of care. Read More
South Korea will implement a new regulation on synthetic biology in April 2026, aiming to foster innovations across both biotechnology and biomanufacturing. Read More
Biopharma happenings, including deals and partnerships, and other news in brief: Astrazeneca, Boehringer Ingelheim, Bostongene, Cartography, Convergent, Day One, Galapagos, Gasherbrum, Genentech, Gilead, Factor, Immuneonco, Instil, Lineage Cell, Mersana, Northstar Medical Radioisotopes, Onconano, Pfizer, Variant. Read More
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Alkermes, Ark, Bioarctic, Biogen, Biosplice, Cellenkos, Eisai, GSK, Johnson & Johnson, Milestone, Oculis, Zai Lab. Read More
Effective Jan. 5, 2026, BioWorld is switching email fulfillment services. While we have made every effort to ensure that all current user subscription details — as well as information on users who have unsubscribed — have been migrated accurately to the new system, there may be a few instances where certain information may not have carried over as expected. If you have any concerns that you received a newsletter in error or if a colleague has not received an expected newsletter, do not hesitate to reach out to our customer care team. Call us:
Americas: 855-258-3279
Europe, Middle East, and Africa: +44 8081 963232
Going forward, if you would like to be unsubscribed, click on the ‘Unsubscribe’ link at the bottom of the emailed newsletter.
